|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CADPS |
Gene summary for CADPS |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CADPS | Gene ID | 8618 |
| Gene name | calcium dependent secretion activator | |
| Gene Alias | CADPS1 | |
| Cytomap | 3p14.2 | |
| Gene Type | protein-coding | GO ID | GO:0001505 | UniProtAcc | Q9ULU8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8618 | CADPS | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.40e-12 | 4.17e-01 | 0.0155 |
| 8618 | CADPS | HTA11_2951_2000001011 | Human | Colorectum | AD | 2.55e-06 | 7.51e-01 | 0.0216 |
| 8618 | CADPS | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.39e-47 | 1.70e+00 | -0.0811 |
| 8618 | CADPS | HTA11_78_2000001011 | Human | Colorectum | AD | 4.90e-30 | 1.29e+00 | -0.1088 |
| 8618 | CADPS | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.28e-06 | 4.84e-01 | -0.1207 |
| 8618 | CADPS | HTA11_696_2000001011 | Human | Colorectum | AD | 9.47e-21 | 7.07e-01 | -0.1464 |
| 8618 | CADPS | HTA11_866_2000001011 | Human | Colorectum | AD | 1.65e-15 | 6.05e-01 | -0.1001 |
| 8618 | CADPS | HTA11_1391_2000001011 | Human | Colorectum | AD | 5.70e-42 | 1.71e+00 | -0.059 |
| 8618 | CADPS | HTA11_866_3004761011 | Human | Colorectum | AD | 6.06e-07 | 3.08e-01 | 0.096 |
| 8618 | CADPS | HTA11_10711_2000001011 | Human | Colorectum | AD | 8.95e-11 | 5.54e-01 | 0.0338 |
| 8618 | CADPS | HTA11_7696_3000711011 | Human | Colorectum | AD | 7.11e-16 | 4.85e-01 | 0.0674 |
| 8618 | CADPS | HTA11_6818_2000001011 | Human | Colorectum | AD | 5.17e-04 | 4.92e-01 | 0.0112 |
| 8618 | CADPS | HTA11_6818_2000001021 | Human | Colorectum | AD | 4.00e-22 | 9.66e-01 | 0.0588 |
| 8618 | CADPS | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.20e-13 | 4.89e-01 | 0.3859 |
| 8618 | CADPS | HTA11_99999973899_84307 | Human | Colorectum | MSS | 9.55e-14 | 6.63e-01 | 0.2585 |
| 8618 | CADPS | F007 | Human | Colorectum | FAP | 1.47e-18 | 9.10e-01 | 0.1176 |
| 8618 | CADPS | A002-C-010 | Human | Colorectum | FAP | 2.31e-20 | 6.60e-01 | 0.242 |
| 8618 | CADPS | A001-C-207 | Human | Colorectum | FAP | 5.37e-13 | 6.89e-01 | 0.1278 |
| 8618 | CADPS | A015-C-204 | Human | Colorectum | FAP | 1.15e-04 | 4.61e-01 | -0.0228 |
| 8618 | CADPS | A002-C-201 | Human | Colorectum | FAP | 3.62e-16 | 7.15e-01 | 0.0324 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00171574 | Cervix | CC | regulation of exocytosis | 39/2311 | 202/18723 | 2.90e-03 | 1.93e-02 | 39 |
| GO:00068873 | Cervix | CC | exocytosis | 59/2311 | 352/18723 | 8.74e-03 | 4.48e-02 | 59 |
| GO:0045921 | Colorectum | AD | positive regulation of exocytosis | 33/3918 | 86/18723 | 1.58e-04 | 2.20e-03 | 33 |
| GO:0051047 | Colorectum | AD | positive regulation of secretion | 90/3918 | 310/18723 | 4.11e-04 | 4.66e-03 | 90 |
| GO:1903532 | Colorectum | AD | positive regulation of secretion by cell | 82/3918 | 282/18723 | 6.85e-04 | 7.00e-03 | 82 |
| GO:0006887 | Colorectum | AD | exocytosis | 96/3918 | 352/18723 | 2.48e-03 | 1.90e-02 | 96 |
| GO:0017157 | Colorectum | AD | regulation of exocytosis | 59/3918 | 202/18723 | 3.20e-03 | 2.36e-02 | 59 |
| GO:0099003 | Colorectum | AD | vesicle-mediated transport in synapse | 57/3918 | 200/18723 | 6.53e-03 | 4.06e-02 | 57 |
| GO:00459211 | Colorectum | SER | positive regulation of exocytosis | 25/2897 | 86/18723 | 9.88e-04 | 1.17e-02 | 25 |
| GO:00068871 | Colorectum | SER | exocytosis | 75/2897 | 352/18723 | 2.05e-03 | 2.03e-02 | 75 |
| GO:00510471 | Colorectum | SER | positive regulation of secretion | 65/2897 | 310/18723 | 5.71e-03 | 4.19e-02 | 65 |
| GO:00171571 | Colorectum | SER | regulation of exocytosis | 45/2897 | 202/18723 | 6.46e-03 | 4.63e-02 | 45 |
| GO:19035321 | Colorectum | MSS | positive regulation of secretion by cell | 74/3467 | 282/18723 | 7.93e-04 | 8.36e-03 | 74 |
| GO:00510472 | Colorectum | MSS | positive regulation of secretion | 80/3467 | 310/18723 | 8.55e-04 | 8.75e-03 | 80 |
| GO:00990031 | Colorectum | MSS | vesicle-mediated transport in synapse | 54/3467 | 200/18723 | 1.94e-03 | 1.67e-02 | 54 |
| GO:00459212 | Colorectum | MSS | positive regulation of exocytosis | 27/3467 | 86/18723 | 2.76e-03 | 2.17e-02 | 27 |
| GO:0099504 | Colorectum | MSS | synaptic vesicle cycle | 48/3467 | 181/18723 | 4.85e-03 | 3.39e-02 | 48 |
| GO:00990032 | Colorectum | FAP | vesicle-mediated transport in synapse | 51/2622 | 200/18723 | 1.09e-05 | 3.08e-04 | 51 |
| GO:00995041 | Colorectum | FAP | synaptic vesicle cycle | 45/2622 | 181/18723 | 6.73e-05 | 1.28e-03 | 45 |
| GO:0023061 | Colorectum | FAP | signal release | 94/2622 | 463/18723 | 1.06e-04 | 1.76e-03 | 94 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CADPS | SNV | Missense_Mutation | novel | c.3511G>A | p.Glu1171Lys | p.E1171K | Q9ULU8 | protein_coding | deleterious(0.02) | probably_damaging(0.98) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| CADPS | SNV | Missense_Mutation | rs755694732 | c.3902N>A | p.Arg1301Gln | p.R1301Q | Q9ULU8 | protein_coding | tolerated(0.05) | probably_damaging(0.978) | TCGA-A2-A0ER-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| CADPS | SNV | Missense_Mutation | c.3309N>C | p.Met1103Ile | p.M1103I | Q9ULU8 | protein_coding | deleterious(0) | possibly_damaging(0.885) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CADPS | SNV | Missense_Mutation | rs772497329 | c.3956N>A | p.Arg1319Gln | p.R1319Q | Q9ULU8 | protein_coding | tolerated(0.33) | probably_damaging(0.978) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CADPS | SNV | Missense_Mutation | c.3748N>A | p.Glu1250Lys | p.E1250K | Q9ULU8 | protein_coding | deleterious(0) | possibly_damaging(0.86) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| CADPS | SNV | Missense_Mutation | rs751860249 | c.3742N>A | p.Val1248Ile | p.V1248I | Q9ULU8 | protein_coding | tolerated(0.46) | benign(0.003) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CADPS | SNV | Missense_Mutation | c.1949N>T | p.Ala650Val | p.A650V | Q9ULU8 | protein_coding | deleterious(0.03) | probably_damaging(0.985) | TCGA-B6-A0RQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CADPS | SNV | Missense_Mutation | rs774706010 | c.767N>T | p.Ala256Val | p.A256V | Q9ULU8 | protein_coding | tolerated(0.23) | benign(0.026) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CADPS | SNV | Missense_Mutation | novel | c.1841N>G | p.Leu614Arg | p.L614R | Q9ULU8 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-BH-A18K-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| CADPS | SNV | Missense_Mutation | c.2948N>C | p.Arg983Thr | p.R983T | Q9ULU8 | protein_coding | deleterious(0) | benign(0.162) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |